Clinical Trial Update: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period [Phase 3]

View source ↗

Summary

A Phase 3 study evaluates the efficacy and safety of TAK-279 for moderate-to-severe plaque psoriasis over 60 weeks, including withdrawal and retreatment periods…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• TAK-279

Snippet

Sponsor: Takeda | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED